Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Endres

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Molecular Pharmacology|November 24, 2004
Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamoleChristopher J Endres, Jashvant D Unadkat
The Biochemical Journal|February 5, 2004
Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1Christopher J Endres, Dhruba J Sengupta, Jashvant D Unadkat
Molecular Pharmaceutics|November 6, 2009
Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement?Christopher J Endres, Michael G Endres, Jashvant D Unadkat
Physics in Medicine and Biology|March 29, 2011
Reference tissue modeling with parameter coupling: application to a study of SERT binding in HIVChristopher J Endres, Dima A Hammoud, Martin G Pomper
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 21, 2005
The role of transporters in drug interactionsChristopher J Endres, Peng Hsiao, Francisco S Chung, et al.
Nuclear Medicine and Biology|March 8, 2003
Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methodsChristopher J Endres, Badreddine Bencherif, John Hilton, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose studyDavid H Salinger, Christopher J Endres, David A Martin, et al.
Biopharmaceutics & Drug Disposition|May 20, 2016
The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouseChristopher J Endres, Aaron M Moss, Kazuya Ishida, et al.
Clinical Pharmacokinetics|October 5, 2024
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal CancerDaping Zhang, Adekemi Taylor, Jie Janet Zhao, et al.
Neuroimage|May 3, 2003
Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue modelYun Zhou, Christopher J Endres, James Robert Brasić, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Molecular Pharmacology|November 24, 2004
Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamoleChristopher J Endres, Jashvant D Unadkat
The Biochemical Journal|February 5, 2004
Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1Christopher J Endres, Dhruba J Sengupta, Jashvant D Unadkat
Molecular Pharmaceutics|November 6, 2009
Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement?Christopher J Endres, Michael G Endres, Jashvant D Unadkat
Physics in Medicine and Biology|March 29, 2011
Reference tissue modeling with parameter coupling: application to a study of SERT binding in HIVChristopher J Endres, Dima A Hammoud, Martin G Pomper
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 21, 2005
The role of transporters in drug interactionsChristopher J Endres, Peng Hsiao, Francisco S Chung, et al.
Nuclear Medicine and Biology|March 8, 2003
Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methodsChristopher J Endres, Badreddine Bencherif, John Hilton, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose studyDavid H Salinger, Christopher J Endres, David A Martin, et al.
Biopharmaceutics & Drug Disposition|May 20, 2016
The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouseChristopher J Endres, Aaron M Moss, Kazuya Ishida, et al.
Clinical Pharmacokinetics|October 5, 2024
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal CancerDaping Zhang, Adekemi Taylor, Jie Janet Zhao, et al.
Neuroimage|May 3, 2003
Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue modelYun Zhou, Christopher J Endres, James Robert Brasić, et al.
Pageof 5